Measure ID
PAIN-03
Description

Percentage of patients requiring the use of naloxone for opioid reversal.

Measure Type
Outcome
Available for Provider Feedback
Yes
Threshold
Not applicable - Informational only
Rationale

Opioid overdose can lead to respiratory depression, brain damage, and even death. Adverse effects related to opioid administration may require administration of an opioid antagonist such as naloxone, which needs to be titrated in order to partially maintain analgesic effects as rapid reversal of opioid can lead to hypertension, pulmonary edema, tachycardia, or myocardial ischemia. Judicious use of opioids for patients that have planned extubation at the end of the case can avoid use of reversal agents and their side effects.  In an anesthetized patient, respiratory depression due to opioid administration negatively impacts attempts to maintain spontaneous ventilation, thus contributing to delayed extubation. For patients not meeting extubation requirements due to opioids or benzodiazepines, waiting until the effects wear off is preferable to reversal administration.1-4

Measure Time Period
Inclusions

Patients who recieved opioids intraoperatively or in the immediate postoperative period.

Exclusions
  • ASA 5 & 6 cases including Organ Procurement (CPT: 01990)
  • Cases where naloxone is administered before the first dose of opioid
  • Patients not given opioids during the intraoperative or recovery period
  • Patients that are still intubated at anesthesia end (as determined by no Extubation Time recorded for the case)
  • ECT
Success Criteria

Appropriate dosing of opioid administration where naloxone administration for reversal was avoided.

Other Measure Details

*This measure will include only valid MPOG cases as defined by the Is Valid Case phenotype.

Risk Adjustment

Pending.

Provider Attribution

Provider(s) signed in between Anesthesia Start and PACU End.

MPOG Concept Used

Opioid (IV and Oral)

  • 10306 Morphine
  • 10186 Fentanyl
  • 10219 Hydromorphone
  • 10414 Sufentanil
  • 10290 Methadone
  • 10020 Alfentanil
  • 10187 Fentanyl/Midazolam 40mcg/mL/200mcg/mL
  • 10279 Meperidine
  • 10341 Oxycodone
  • 10414 Sufentanil
  • 10481 Oxycodone/Acetaminophen 5mg/325mg
  • 10482 Hydrocodone/Acetaminophen 5mg/325mg
  • 10483 Hydrocodone/Acetaminophen 7.5mg/500mg
  • 10597 Propofol w/ Alfentanil 10mg/mL + 50mcg/mL

Reversal

  • 10312 Naloxone
MPOG Phenotypes Used
References
  1. Lee LA, Caplan RA, Stephens LS, Posner  KL, Terman GW, Voepel-Lewis T, Domino KB. Postoperative opioid- induced respiratory depression: A closed claims analysis. Anesthesiology. 2015;122(3):659-665.
  2. Ramachandran SK, Haider N, Saran KA, Mathis M, Kim J, Morris M, O’Reilly M. Life-threatening critical respiratory events: A retrospective study of postoperative patients found unresponsive during analgesic therapy. J Clin Anesth. 2011;23:207–13.
  3. Alexander JC, Patel B, Joshi GP. Perioperative use of opioids: Current controversies and concerns. Best Practice & Research Clinical Anaesthesiology 2019; 33:341–51 https://doi.org/10.1016/j.bpa.2019.07.009.
Measure Authors

 Measure Author

 Institution

 Henrietta Addo, MSN, RN

 University of Michigan

 Nirav Shah, MD

 University of Michigan

 Rob Coleman

 University of Michigan

 

Measure Reviewer(s)
Date Reviewed Reviewer Institution Summary QC Vote
N/A N/A N/A N/A N/A

 

Version

Published Date: 09/2023

Date Criteria Revision